Key Takeaways
- In 324 transplant patients, gut microbiome diversity at engraftment did not predict non-relapse deaths at one year.
- Diversity measured before transplant did matter: patients with the lowest baseline diversity had shorter overall survival.
- The finding challenges earlier observational links between low diversity at engraftment and worse outcomes.
A surprising result from a major transplant study
The diversity of bacteria living in a patient's gut may matter differently depending on when it is measured during stem-cell transplantation. A prospective study published in Nature Medicine found that gut microbiome diversity measured at engraftment was not significantly associated with survival or other clinical outcomes. However, diversity measured before transplant conditioning was associated with subsequent survival. The findings challenge earlier observational research suggesting that low gut bacterial diversity around engraftment is a strong indicator of poor transplant outcomes.
How the study worked
The analysis was conducted within BMT CTN 1801, a phase 3 randomized clinical trial involving 324 adults with blood cancers undergoing allogeneic hematopoietic stem-cell transplantation. In this procedure, patients receive blood-forming stem cells from a donor to rebuild their blood and immune systems. Of the 324 participants, 304 provided stool samples, and researchers sequenced 2,575 samples to examine changes in gut bacterial diversity. Engraftment occurs when transplanted donor stem cells begin producing new blood cells, typically identified by recovery of neutrophils, an important type of white blood cell. The study's prespecified primary question was whether microbiome diversity at engraftment was associated with non-relapse mortality within one year. Non-relapse mortality refers to deaths from causes other than the underlying cancer returning. Researchers found no statistically significant association, whether bacterial diversity was analyzed in thirds or as a continuous measurement. Diversity at engraftment was also not significantly associated with other evaluated clinical outcomes, including overall survival, relapse and graft-versus-host disease.
The baseline told a different story
Researchers observed a different pattern when they examined stool samples collected before conditioning treatment, which involves chemotherapy or radiation to prepare patients for transplantation. Patients with the lowest baseline gut microbiome diversity had significantly shorter overall survival than those with the highest diversity. Baseline diversity was also associated with graft-versus-host-disease-free, relapse-free survival, a composite measure used to assess transplant outcomes. These findings suggest that the gut microbiome's condition before treatment may provide information about a patient's subsequent clinical course. However, the associations do not establish that low bacterial diversity directly causes poorer survival.
Treatment changed the microbiome, but not as expected
Gut bacterial diversity declined after transplantation in both treatment groups. The decline was greater among patients receiving post-transplant cyclophosphamide, a treatment used to help prevent graft-versus-host disease. Yet that treatment arm had better one-year outcomes in the parent randomized trial. This apparent contradiction is important because it suggests that changes in microbiome diversity after transplantation do not necessarily translate directly into worse clinical outcomes. The findings also raise questions about whether gut microbiome diversity measured at engraftment is a reliable indicator of transplant risk across different treatment approaches.
The Twikup Take
This study challenges a seemingly straightforward assumption: that lower gut bacterial diversity around stem-cell engraftment necessarily signals worse survival. Instead, the researchers found a meaningful association before conditioning treatment, while diversity at engraftment showed no statistically significant relationship with the outcomes examined. The distinction matters. A microbiome measurement may offer useful information about a patient's health without being a direct cause of what happens next. For now, the findings support further investigation of the pre-transplant microbiome, not the conclusion that changing gut bacteria will improve survival. The study covered reduced-intensity conditioning only, and diet was not recorded. Image: Illustrative image.